Synergistic Combinations for Improved Therapeutic Outcomes in Triple Negative Breast Cancer

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapy options, leading to poor prognosis.
• Current treatment limitations necessitate novel therapeutic strategies for TNBC management.

Purpose of the Study:

• To review mechanistic insights and translational data supporting synergy-driven polytherapy for TNBC.
• To highlight the potential of combination regimens in overcoming therapeutic resistance and improving outcomes.

Main Methods:

• Review of preclinical and clinical studies on combination therapies in TNBC.
• Analysis of synergistic mechanisms involving dual signalling blockade, DNA repair inhibition, and immunotherapy integration.

Main Results:

• Synergistic combinations, including PI3K/AKT and MAPK pathway blockade, PARP inhibitors with ATR/WEE1 inhibitors, and immunotherapy combinations, demonstrate enhanced tumor control.
• These strategies disrupt adaptive resistance, promote immunogenic cell death, and remodel the tumor microenvironment.

Conclusions:

• Synergy-based polytherapy represents a foundational paradigm shift in TNBC management.
• Combination regimens hold the potential to convert transient responses into durable remissions for TNBC patients.